Assuntina Sacco, MD
Hematology & Oncology · Ann Arbor, MINPI 1871757831
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,540 of the $4,161 with a category attached, or 61.0%. Pfizer accounts for 61.0% of it on its own, with 4 other manufacturers making up the rest.
Across 8 payments — averaging $520.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$3K
- Janssen Scientific Affairs, LLC$1K
- Eisai Inc.$120
- E.r. Squibb & Sons, L.L.C.$96
- Merck$18
Across 121 payments — averaging $66,918 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$7.4M
- Pfizer$388K
- Genentech, Inc.$135K
- Regeneron$107K
- Astrazeneca UK Limited$17K
What the payments were for
- Consulting fees$1,38833%
- Speaking & faculty fees$2,54061%
- Food & beverage$2165%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 4 | $2,540 |
| Janssen Scientific Affairs, LLC | 1 | $1,388 |
| Eisai Inc. | 1 | $120 |
| E.r. Squibb & Sons, L.L.C. | 1 | $96 |
| Merck | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,161 in reported general payments places this provider in the 65th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 28 | $1,192 |
| Gabapentin | 38 | $782 |
| Levothyroxine Sodium | 72 | $374 |
| Ketoconazole | 13 | $299 |
| Triamcinolone Acetonide | 25 | $203 |
| Prochlorperazine Maleate | 20 | $198 |
| Lidocaine Hcl ViscousLidocaine Hcl | 15 | $173 |
| Prednisone | 16 | $87 |
| Dexamethasone | 13 | $69 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Ann Arbor
- Jason BrownAnn Arbor$35K
- Ibrahim SahinAnn Arbor$34K
- Jonathan WeissAnn Arbor$14K
- Vedran RadojcicAnn Arbor$11K
- Faisal MusaDearborn$976K
- Mohammed Al HallakDetroit$644K
- Daniel LebovicGrosse Pointe Woods$352K
- Sreenivasa ChandanaGrand Rapids$305K
- Mohammad ChistiTroy$180K
- Gordon SrkalovicLansing$167K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.